Abstract
Background and Aims : GALNT2, encoding polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-T2), was initially discovered as a regulator of high-density lipoprotein metabolism. GalNAc-T2 is known to exert these effects through post-translational modification, i.e., O-linked glycosylation of secreted proteins including apolipoprotein C-III, angiopoietin-like 3 and phospholipid transfer protein with established roles in plasma lipid metabolism. More recently it has become clear that loss of GALNT2 in rodents, cattle, nonhuman primates and humans should be regarded as a novel congenital disorder of glycosylation which affects energy metabolism, a topic that has not yet been specifically addressed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
